Ductal prostate cancer

Contemporary management and outcomes

Eduardo Orihuela, Justin M. Green

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objectives: To evaluate contemporary management and outcomes of ductal prostate cancer (PCA). Materials and Methods: We reviewed all patients with ductal PCA and at least 6 months of follow-up seen at UTMB from 1990 to 2005, which comprised 17 patients (mean age: 67.7 years, range 55-87). At time of diagnosis, 11 patients had localized disease (Group 1) and 6 patients had distant metastasis (Group 2). Results: Treatment of Group 1 patients included radiation and endocrine treatment for at least 2 years (n = 7), radiation alone (n = 2), and radical surgery (n = 2). At a mean follow-up of 3.6 years (r = 1-12 years) 8 patients (67.7%) remained free of recurrence, 1 patient had biochemical recurrence alone, 1 patient had recurrence in the anterior urethra, and the other had progression with metastasis to the brain and subsequent death. In addition to metastasis to regional/distant lymph nodes and bone in Group 2, metastatic sites included brain (n = 1), peritoneum (n = 1), and lung (n = 1). Mean follow-up was 2.3 years (r = 8 months to 4 years). All patients received androgen deprivation. One patient had progression of disease despite lack of biochemical recurrence and is alive at 2.5 years. One patient died from other causes while the 4 remaining patients are in remission at last follow-up. Conclusions: Contemporary management of localized ductal PCA with radiation and endocrine therapy yields adequate disease-free survival. Metastatic sites include brain, lung, peritoneum, and anterior urethra, and most patients respond well to endocrine treatment.

Original languageEnglish (US)
Pages (from-to)368-371
Number of pages4
JournalUrologic Oncology: Seminars and Original Investigations
Volume26
Issue number4
DOIs
StatePublished - Jul 2008

Fingerprint

Prostatic Neoplasms
Recurrence
Peritoneum
Urethra
Neoplasm Metastasis
Radiation
Lung
Brain Death
Brain
Androgens
Disease-Free Survival
Disease Progression
Radiotherapy
Therapeutics
Lymph Nodes
Bone and Bones

Keywords

  • Ductal
  • Endometrioid
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Ductal prostate cancer : Contemporary management and outcomes. / Orihuela, Eduardo; Green, Justin M.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 26, No. 4, 07.2008, p. 368-371.

Research output: Contribution to journalArticle

Orihuela, Eduardo ; Green, Justin M. / Ductal prostate cancer : Contemporary management and outcomes. In: Urologic Oncology: Seminars and Original Investigations. 2008 ; Vol. 26, No. 4. pp. 368-371.
@article{9f3f5b3ce4784519b9d98726e317cdd4,
title = "Ductal prostate cancer: Contemporary management and outcomes",
abstract = "Objectives: To evaluate contemporary management and outcomes of ductal prostate cancer (PCA). Materials and Methods: We reviewed all patients with ductal PCA and at least 6 months of follow-up seen at UTMB from 1990 to 2005, which comprised 17 patients (mean age: 67.7 years, range 55-87). At time of diagnosis, 11 patients had localized disease (Group 1) and 6 patients had distant metastasis (Group 2). Results: Treatment of Group 1 patients included radiation and endocrine treatment for at least 2 years (n = 7), radiation alone (n = 2), and radical surgery (n = 2). At a mean follow-up of 3.6 years (r = 1-12 years) 8 patients (67.7{\%}) remained free of recurrence, 1 patient had biochemical recurrence alone, 1 patient had recurrence in the anterior urethra, and the other had progression with metastasis to the brain and subsequent death. In addition to metastasis to regional/distant lymph nodes and bone in Group 2, metastatic sites included brain (n = 1), peritoneum (n = 1), and lung (n = 1). Mean follow-up was 2.3 years (r = 8 months to 4 years). All patients received androgen deprivation. One patient had progression of disease despite lack of biochemical recurrence and is alive at 2.5 years. One patient died from other causes while the 4 remaining patients are in remission at last follow-up. Conclusions: Contemporary management of localized ductal PCA with radiation and endocrine therapy yields adequate disease-free survival. Metastatic sites include brain, lung, peritoneum, and anterior urethra, and most patients respond well to endocrine treatment.",
keywords = "Ductal, Endometrioid, Prostate cancer",
author = "Eduardo Orihuela and Green, {Justin M.}",
year = "2008",
month = "7",
doi = "10.1016/j.urolonc.2007.05.028",
language = "English (US)",
volume = "26",
pages = "368--371",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Ductal prostate cancer

T2 - Contemporary management and outcomes

AU - Orihuela, Eduardo

AU - Green, Justin M.

PY - 2008/7

Y1 - 2008/7

N2 - Objectives: To evaluate contemporary management and outcomes of ductal prostate cancer (PCA). Materials and Methods: We reviewed all patients with ductal PCA and at least 6 months of follow-up seen at UTMB from 1990 to 2005, which comprised 17 patients (mean age: 67.7 years, range 55-87). At time of diagnosis, 11 patients had localized disease (Group 1) and 6 patients had distant metastasis (Group 2). Results: Treatment of Group 1 patients included radiation and endocrine treatment for at least 2 years (n = 7), radiation alone (n = 2), and radical surgery (n = 2). At a mean follow-up of 3.6 years (r = 1-12 years) 8 patients (67.7%) remained free of recurrence, 1 patient had biochemical recurrence alone, 1 patient had recurrence in the anterior urethra, and the other had progression with metastasis to the brain and subsequent death. In addition to metastasis to regional/distant lymph nodes and bone in Group 2, metastatic sites included brain (n = 1), peritoneum (n = 1), and lung (n = 1). Mean follow-up was 2.3 years (r = 8 months to 4 years). All patients received androgen deprivation. One patient had progression of disease despite lack of biochemical recurrence and is alive at 2.5 years. One patient died from other causes while the 4 remaining patients are in remission at last follow-up. Conclusions: Contemporary management of localized ductal PCA with radiation and endocrine therapy yields adequate disease-free survival. Metastatic sites include brain, lung, peritoneum, and anterior urethra, and most patients respond well to endocrine treatment.

AB - Objectives: To evaluate contemporary management and outcomes of ductal prostate cancer (PCA). Materials and Methods: We reviewed all patients with ductal PCA and at least 6 months of follow-up seen at UTMB from 1990 to 2005, which comprised 17 patients (mean age: 67.7 years, range 55-87). At time of diagnosis, 11 patients had localized disease (Group 1) and 6 patients had distant metastasis (Group 2). Results: Treatment of Group 1 patients included radiation and endocrine treatment for at least 2 years (n = 7), radiation alone (n = 2), and radical surgery (n = 2). At a mean follow-up of 3.6 years (r = 1-12 years) 8 patients (67.7%) remained free of recurrence, 1 patient had biochemical recurrence alone, 1 patient had recurrence in the anterior urethra, and the other had progression with metastasis to the brain and subsequent death. In addition to metastasis to regional/distant lymph nodes and bone in Group 2, metastatic sites included brain (n = 1), peritoneum (n = 1), and lung (n = 1). Mean follow-up was 2.3 years (r = 8 months to 4 years). All patients received androgen deprivation. One patient had progression of disease despite lack of biochemical recurrence and is alive at 2.5 years. One patient died from other causes while the 4 remaining patients are in remission at last follow-up. Conclusions: Contemporary management of localized ductal PCA with radiation and endocrine therapy yields adequate disease-free survival. Metastatic sites include brain, lung, peritoneum, and anterior urethra, and most patients respond well to endocrine treatment.

KW - Ductal

KW - Endometrioid

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=45849119461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849119461&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2007.05.028

DO - 10.1016/j.urolonc.2007.05.028

M3 - Article

VL - 26

SP - 368

EP - 371

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -